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Abstract: 
The goal was to predict pressure reactivity index (PRx) using non-invasive transcranial Doppler (TCD) 
based indices of cerebrovascular reactivity, systolic flow index (Sx_a) and mean flow index (Mx_a). 
Continuous extended duration time series recordings of middle cerebral artery cerebral blood flow 
velocity (CBFV) were obtained using robotic TCD in parallel with direct intracranial pressure (ICP).  PRx, 
Sx_a and Mx_a were derived from high frequency archived signals.  Using time-series techniques, 
autoregressive integrative moving average (ARIMA) structure of PRx was determined and embedded in 
the following linear mixed effects (LME) models of PRx:  PRx ~ Sx_a and PRx ~ Sx_a + Mx_a. Using 80% of 
the recorded patient data, the LME models were created and trained. Model superiority was assessed 
via Akaike information criterion (AIC), Bayesian information criterion (BIC) and log-likelihood (LL).  The 
superior two models were then used to predict PRx using the remaining 20% of the signal data. 
Predicted and observed PRx were compared via Pearson correlation, linear models and Bland-Altman 
(BA) analysis. Ten patients had 3 to 4 hours of continuous uninterrupted ICP and TCD data and were 
used for this pilot analysis. Optimal ARIMA structure for PRx was determined to be (2,0,2), and this was 
embedded in all LME models.  The top two LME models of PRx were determined to be: PRx ~ Sx_a and 
PRx ~ Sx_a + Mx_a. Estimated and observed PRx values from both models were strongly correlated 
(r>0.9; p<0.0001 for both), with acceptable agreement on BA analysis. Predicted PRx using these two 
models was also moderately correlated with observed PRx, with acceptable agreement (r=0.797, 
p=0.006; r=0.763, p=0.011; respectively). With application of ARIMA and LME modelling, it is possible to 
predict PRx using non-invasive TCD measures.  This is the first and preliminary attempts at doing so.  
Much further work is required. Keywords:  autoregulation, brain injury, TBI, TCD, time series 
 
Introduction: 
Pressure reactivity index (PRx) is considered the “gold standard” of continuous cerebrovascular 
reactivity monitoring after traumatic brain injury (TBI).1,2 Derived from the moving correlation 
coefficient between slow-wave fluctuations in intra-cranial pressure (ICP) and mean arterial pressure 
(MAP), PRx provides a continuously updating assessments of cerebral autoregulation, with positive 
values indicative of impaired cerebrovascular reactivity.1,3  Numerous observational studies have linked 
persistently positive PRx values with poor global outcome in TBI, with well-defined critical thresholds 
associated with morbidity and mortality.4,5  Furthermore, PRx is one of only a few continuous indices of 
cerebrovascular reactivity to have been validated for  assessing the lower limit of autoregulation in an 
experimental model.6  Finally, current applications of continuously updating indices of cerebrovascular 
reactivity have focused on the derivation of “personalized” cerebral perfusion pressure (CPP) targets 
(also referred to as CPP optimum), utilizing PRx.7,8 However, the requirement of invasive ICP 
measurements for PRx calculation is a limitation of the technique.   
Various other continuous indices of cerebrovascular reactivity exist based on other invasive and non-
invasive monitoring devices employed after TBI.3,9  In particular, non-invasive transcranial Doppler (TCD) 
can be utilized to derive flow-based  indices.4,10  Recent multi-variate co-variance analysis has confirmed 
a close association between non-invasive TCD derived systolic flow index (Sx_a) – the moving correlation 
between systolic flow velocity (FVs) and MAP) and invasively derived ICP based indices, including 
PRx.11,12  Furthermore, time series linear modelling techniques highlight this strong relationship between 
PRx and Sx_a, while providing evidence to support the ability to estimate PRx accurately using this non-
invasive TCD index.13   
The next natural step would be to attempt the prediction of PRx using this non-invasive TCD measure.  
This has never been attempted before, given complexity of analysis and limitations surrounding 
acquisition of continuous longer uninterrupted TCD recordings.  The goal of this study was to outline the 
first experience at predicting PRx using non-invasive Sx_a, derived from extended duration robotic TCD 
recordings. 
 
Methods: 
 
Patient Population 
The data utilized in this retrospective analysis was part of a prospective observational study conducted 
over a 6-month period within our unit (December 2017- May 2018).  All patients suffered from 
moderate to severe TBI and were admitted to the neurosciences critical care unit (NCCU) at 
Addenbrooke’s Hospital, Cambridge.  Patients were intubated and sedated given the severity of their 
TBI.  Invasive ICP monitoring was conducted in accordance with the Brain Trauma Foundation (BTF) 
guidelines.  Therapeutic measures were directed at maintaining ICP less than 20 mmHg and CPP greater 
than 60 mmHg (datum at the tragus).   
TCD monitoring is a part of standard intermittent cerebral monitoring within the NCCU.  The application 
of the newer robotic TCD device (see description below) was therefore in alignment with our usual care, 
negating the need for formal direct or proxy consent.  All data related to patient admission 
demographics and high frequency digital signals from monitoring devices were collected in an entirely 
anonymous format and ethical approval for research using anonymous data acquired as part of clinical 
practice is not required under UK regulations.  
 
 
Signal Acquisition 
Various signals were obtained through a combination of invasive and non-invasive methods.  Arterial 
blood pressure (ABP) was obtained through either radial or femoral arterial lines connected to pressure 
transducers (Baxter Healthcare Corp. CardioVascular Group, Irvine, CA).  ICP was acquired via an intra-
parenchymal strain gauge probe (Codman ICP MicroSensor; Codman & Shurtleff Inc., Raynham, MA).  
Finally, TCD assessment of MCA CBFV was conducted via a robotic TCD system, the Delica EMS 9D 
(Delica, Shenzhen, China, www.delicasz.com). This system allows for continuous extended duration 
recording of MCA CBFV, using robotically controlled TCD probes, with automated correction algorithms 
for probe shift.  To our knowledge, this is the first study on the application of extended duration TCD 
acquisition via a robotic system in critically ill TBI patients. 
This study aimed to record 3 to 4 hours of continuous data from all devices simultaneously, given the 
previous work from our group on inter-index relationships focused on recording durations of only 0.5 to 
1-hour duration due to limitation of conventional TCD.  As such, this data set also proved to be ideal for 
complex time series modelling and analysis.  Only patients with 3 or more continuous, uninterrupted, 
ICP and TCD recordings were utilized for this study.  Thus, only a sub-population of the group from the 
original study were utilized for this analysis. Figure 1 displays an example of the recording set up, 
including triple bolt, near infrared spectroscopy and robotic TCD. 
 
*Figure 1 here 
 
 
 
 Signal Processing 
Signals were recorded using digital data transfer, sampled at frequency of 100 Hertz (Hz) or higher 
(depending on the modality), using ICM+ software (Cambridge Enterprise Ltd, Cambridge, UK, 
http://icmplus.neurosurg.cam.ac.uk).  Signal artifact were removed using a combination of manual and 
semi-automated methods within ICM+ prior to further processing or analysis. 
Post-acquisition processing of the above signals was conducted using ICM+ software.  CPP was 
determined using the formula:  CPP = MAP – ICP.  TCD signal was analyzed from the right side in the 
majority of the patients given right frontal placement of ICP monitors.  The only exception to this is 
when we were unable to obtain quality TCD on the right due to poor windows for TCD.  
Systolic flow velocity (FVs) was determined by calculating the maximum flow velocity (FV) over a 1.5 
second window, updated every second.  Diastolic flow velocity (FVd) was calculated using the minimum 
FV over a 1.5 second window, updated every second. Mean flow velocity (FVm) was calculated using 
average FV over a 10 second window, updated every 10 seconds (ie. without data overlap). 
Ten second moving averages (updated every 10 seconds to avoid data overlap) were calculated for all 
recorded signals:  ICP, ABP (which produced MAP), CPP, FVm, FVs and FVd.  These non-overlapping 10-
second moving average values allow focus on slow-wave fluctuations in signals by decimating the signal 
frequency to ~0.1Hz. 
Cerebrovascular reactivity indices were derived in a similar fashion across modalities. PRx:  A moving 
Pearson correlation coefficient was calculated between ICP and MAP using 30 consecutive 10 second 
windows (ie. five minutes of data), updated every minute.  Similar to our previous work on non-invasive 
estimation of PRx using Doppler measures, two non-invasive TCD based indices were also derived:  Mx-a 
(the correlation between FVm and MAP) and  Sx-a (the correlation between FVs and MAP).  Diastolic 
flow index (Dx-a) was not evaluated in this study, given our previous work documenting poor time series 
and linear mixed effects (LME) model performance in relation to PRx.13   
Data for this analysis were provided in the form of a minute by minute time trends of the parameters of 
interest for each patient.  This was extracted from ICM+ in to comma separated values (CSV) datasets, 
which were collated into one continuous data sheet (compiled from all patients).   
 
Statistical Analysis 
Similar statistical modelling approach as seen in our previous work for time series data and LME model 
creation were followed with this data set, and almost identical statistical description to his work will be 
found below.13  Minute-by-minute time series data was utilized for the entirety of the analysis described 
below.  Statistical significance was set at an alpha of less than 0.05.  All statistical analysis was conducted 
using R statistical software (R Core Team (2016). R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/). 
The following packages were utilized during the analysis: tseries, forecast, lubridate and lme4. 
The statistical methods sections to follow will outline the techniques employed to:  [A] estimate the 
autocorrelative structure of PRx in time series; [B] create an accurate model estimating PRx using non-
invasive TCD indices of cerebrovascular reactivity via application of linear mixed effects (LME) modelling 
(with embedded PRx autocorrelative error structure);  [C] assess the correlation and agreement 
between model based estimated PRx and the observed PRx value; and [D] predict PRx using the derived 
LME models and estimated PRx time series data.  For LME model creation/training we utilized the 1st 
80% of the data for each patient, with the remaining 20% utilized for the prediction of PRx using the 
LME models. 
  Autocorrelative Structure of PRx 
Prior to being able to model PRx using TCD based indices, it was necessary to determine the 
autocorrelation structure of PRx.  We used Box-Jenkin’s autoregressive integrative moving average 
(ARIMA) modelling   PRx  to determine:  the autoregressive structure of order “p”, the differencing 
factor or order “d”, and the moving average component of order “q”; commonly denoted “(p,d,q)”.  The 
autoregressive structure refers to the dependence of PRx at time t (denoted PRxt) on previous measures 
of PRx (ie. called “lags”), say at time t-1 (ie. PRxt-1), and so forth (ie. say to PRxt-p), with the order “p” 
indicating how many previous PRx measures PRxt is dependent on.  Stationarity is defined here as the 
presence of a stable variance, autocorrelative structure and mean over time.  Stationarity can be 
introduced by differencing previous PRx measures from current measures, thus removing  trending 
structure from a time series, and allowing further modelling to occur.  The differencing order “d” refers 
to how many previous terms should be included in the differencing process.  Finally, the moving average 
term refers to the need to include the error in the ARIMA model at time t (ie. εt) as well as “q” previous 
error terms (ie. εt-I, i=1..q).  Assuming stationarity (ie. no “d” order), the ARIMA model folds to a general 
ARMA model that can be represented by the following formula: 
PRxt = c + εt +  ∑ 𝜑𝑝𝑖=1 𝑃𝑅𝑥t-i + ∑ 𝜃𝜀
𝑞
𝑖=1 t-i 
Where:  PRxt = PRx at time t, PRxt-i = PRx at time t-i, εt = error at time t, εt-i = error at time t-i, c = 
constant, φ and θ are parameters at time t-i, p = autoregressive order, and q = moving average order. 
The following process was conducted on all patient recordings, in order to derive the optimal ARIMA 
structure for PRx time series. This would provide insight into the approximate best ARIMA structure for 
future LME models. 
First, data had already been artifact cleared and had a 10-second moving average filter applied to the 
data, leading to some data smoothing (as described above in the signal processing section).  Thus, our 
initial step for the ARIMA modelling focused on determining stationarity of the signal.  This was 
assessed, and confirmed, using  three methods.  First, we assessed the autocorrelation function (ACF) 
correlogram for PRx, looking for a rapid decline in significant lags, indicating a stationary signal.  Second, 
we employed the Augmented Dickey Fuller (ADF) test to assess for stationarity. Third, we attempted 
seasonal decomposition using the like-named function in R for each PRx time series, which employs 
locally weighted scatterplot smoothing (LOWESS) to identify seasonal and trend components to a time 
series. All above processes confirmed stationarity within our patient examples. 
Second, the autoregressive structure of PRx was assessed using the ACF correlograms and partial 
autocorrelation function (PACF) correlograms.  ACF correlograms were assessed to see how many 
previous consecutive terms (ie. “lags”) PRx may be dependent upon.  Similarly, the PACF correlograms 
were assessed to see how many non-consecutive previous lags, PRx may be dependent upon. Significant 
level on ACF/PACF correlograms is set at a correlation level of +/-(2/N1/2), where N = sample size. We 
then ran sequential ARMA models for PRx by varying the order “p” from 0 to 3, while also varying the 
moving average order “q” from 0 to 3.  Given our analysis for stationarity confirmed a stationary signal 
within our 10 patient examples, we fixed the differencing order “d” at 0. In doing so we generated 16 
separate ARMA models for PRx within each patient.  Model superiority was assessed by Akaike 
Information Criterion (AIC) and Log-Likelihood (LL), with the lowest AIC and highest LL indicating the 
best ARMA model for PRx.  In addition, model superiority was assessed via residuals, model ACF and 
PACF correlograms, with an adequate model represented by random residuals, and ACF/PACF failing to 
display any lags reaching significance.   
 
LME Modelling of PRx Using TCD Derived Indices 
LME modelling was conducted on the entire patient population. LME modelling involved various fixed 
linear models, and a random component introduced into the intercept and independent variable 
coefficient (based on individual patient).  We embedded the PRx ARIMA structure within the LME 
models (based on the ARIMA modelling results analysis above).  This analysis was done on the full data 
set, deriving LME models for each patient as well as for the entire population. The following LME models 
were assessed, initially with random intercept only (stratified by patient), as above:  PRx ~ Sx_a, PRx ~ 
Mx_a, and PRx ~ Sx_a + Mx_a.  All models were corrected using maximum likelihood estimation method.  
Adequacy of the LME model was assessed via QQ plots and the residuals distribution plot, with linear 
shape to the QQ plots and normally distributed residuals confirming validity of the model.   
Models were compared using AIC, Bayesian Information Criterion (BIC), LL and analysis of variance 
(ANOVA) testing.  Superior models were attributed to the lowest AIC, lowest BIC and highest LL.  
Significance differences between models were assessed by ANOVA testing, with a threshold for 
significance set at a p < 0.05. The top 2 superior LME models were reported in detail, with a final 
assessment of model adequacy through ACF/PACF plots of the model residuals, observing for a minimal 
number of significant lags which decay rapidly.   
Generalized fixed effects models were also created based on the top two LME models. However, these 
models performed poorly, with substantially inferior AIC, BIC and LL values.  In addition, these general 
fixed effects models maintained continuous significant lags in the residuals, further indicating poor 
modelling of PRx.  Hence, these models will not be discussed further.  
 
 
Observed versus Estimated PRx 
We assessed the correlation between the observed (minute-by-minute) PRx values in our population 
versus those estimated from our optimal two LME models using Pearson correlation coefficient.  We 
then produced linear regression plots between observed and estimated PRx for the best two LME 
models, using grand mean data (ie. mean value per patient).  Finally, Bland-Altman plots were produced 
to assess agreement between the observed and estimated PRx values, using grand mean Fisher 
transformed data (ie. Fisher transform applied to both observed and estimated PRx). 
 
Predicting PRx  
We predicted PRx based on the top two LME models from the above discussed methods. Using the LME 
models themselves and the remaining 20% patient data not used in LME creation, we derived predicted 
PRx (pPRx) values from observed Sx-a and Mx-a values within this data subset. The predicted values 
were then compared to the actual observed PRx values during this period using Pearson correlation, 
linear modelling and Bland-Altman analysis.  
 
Results: 
a. Patient Demographics 
A total of 10 patients with moderate/severe TBI had sufficient quality TCD signals (ie. at least 3 – 4 hours 
duration and uninterrupted).  The mean age for this population was 34.5 +/- 17.0 years, with 8 patients 
being male.  The median admission GCS was 7 (IQR 4 to 8), with median admission GCS motor score of 4 
(IQR 2 to 5). The mean duration of ICP/TCD recording was 223.2 +/- 38.4 minutes. Only 80% of the total 
recording duration for each patient was utilized for model formation and training, with the remaining 
20% reserved for predictive testing. 
 
b. Building the Model to Estimate PRx 
 
ARIMA Modelling of PRx  
In all 10 patients the ARIMA structure of PRx was investigated in order to determine the appropriate 
structure for future LME modelling of the entire population.  Upon inspection of the ACF/PACF plots, 
ADF test results and seasonal decomposition techniques, it was determined that no significant trend or 
seasonality were present in any of the 10 patient recordings. Thus, no differencing order “d” was 
introduced.  Next, sequential ARMA models were produced for each patient, varying the autoregressive 
order “p” and moving average order “q”, from 0 to 3.  Across all patients the optimal ARMA model for 
PRx was found to be (2,0,2), based on the principle of parsimony, and the lowest AIC and highest LL. 
Figure 2 displays the ACF and PACF plots of PRx for one patient with 4 hours of continuous recording, 
demonstrating a rapid decay in significant lags (implying stationarity). Figure 3 shows the residuals for 
the ARMA model for PRx in the same patient, with an ARMA structure of (2,0,2).  This figure 
demonstrates a lack of significant lags on ACF and PACF plots, with randomly distributed residuals, 
confirming adequacy of the chosen model.  
 
*Figure 2 and 3 here 
 
 
c. Model Development and Accuracy Assessment 
LME Modelling of PRx Using TCD Indices 
Using the (2,0,2) PRx ARMA structure identified within the individual patients, various LME models 
were produced, embedding the PRx ARMA structure within them. Table 1 displays the model 
characteristics for those LME models derived from Sx_a and Mx_a, introducing random effects by 
patient into the intercept and coefficients. Model superiority was confirmed via ANOVA testing, with 
the lowest AIC/BIC and highest LL, indicating superiority. The top two LME models were:  PRx ~ Sx_a 
(AIC = -1564.957, BIC = -1510.159, LL = 792.4786) and PRx ~ Sx_a + Mx_a (AIC = -1597.345, BIC = -
1520.627, LL = 812.6726); with random effects by patient introduced into both the coefficients and 
intercept.  The QQ and residual density plots for these top two LME models can be seen in Appendix 
A, displaying normally distributed residuals, indicating model adequacy. The ACF and PACF plots for 
these two models can also be found in Appendix A, displaying acceptable rapid decay of significant 
lags.  
 
Population Based Estimation of PRx Using Sx-a and Mx-a 
Using the top two LME models described above, PRx was estimated using the available Sx_a and 
Mx_a measures in the training data set. Grand mean values were calculated per patient and plotted 
against the observed PRx values from the data.  A strong linear relationship was seen between 
estimated and observed PRx using both LME models.  Figure 4 displays estimated versus observed 
PRx plots for each model. The PRx ~ Sx_a model displayed a correlation between estimated and 
observed values of 0.998 (95% CI = 0.990 – 0.999; p<0.0001), while the PRx ~ Sx_a + Mx_a model 
had a correlation between estimated and observed PRx values of 0.997 (95% CI = 0.988 – 0.999; 
p<0.0001).  Bland-Altman analysis on Fisher transformed results displayed acceptable agreement, 
with slight underestimation bias in the estimated PRx for both models.  This bias in the Bland-
Altman plots was seen in our previous work as well.13  Appendix B contains the results of the Bland-
Altman analysis comparing the estimated to observed PRx for both LME models. 
 
 
  
*Table 1 here 
*Figure 4 here 
 
d. Predicting PRx Using Non-Invasive TCD Parameters 
Using the top two LME models derived above, we proceeded to predict PRx (pPRx) using the 20% of data 
not used in model construction/training.  Each patient had 20% of their recording data excluded from 
the prior model formation/training, each with ICP and TCD derived variables, amounting to ~30 to 60 
minutes of minute-by-minute data per patient. For each LME model, the Sx_a and Mx_a values from this 
new data were entered into the models to derive pPRx. Grand mean values were then calculated per 
patient.  For the model PRx ~ Sx_a, the correlation between predicted and observed PRx values was 
0.797 (95% CI = 0.336 – 0.949; p=0.006). Similarly, for the model PRx ~ Sx_a + Mx_a, the correlation 
between predicted and observed PRx was 0.763 (95% CI = 0.258 – 0.941; p=0.011). Predicted and 
observed PRx values displayed a linear association, though not 1:1.  Figure 5 displays the predicted 
versus observed PRx plots for the top two LME models. Bland-Altman analysis of Fisher transformed 
data demonstrated acceptable agreement between predicted and observed PRx values, with similar 
underestimation of the predicted PRx values as seen in the training data previously. All Bland-Altman 
results for comparing pPRx to observed PRx can be found in Appendix C.  
 
*Figure 5 here 
 
Discussion: 
Through the application of time-series ARMA and LME modelling in this pilot study we have been able to 
describe, for the first time, the prediction of pressure reactivity index PRx using non-invasive TCD 
derived cerebral autoregulation measures (in this case Sx_a and Mx_a).  Some important aspects of this 
preliminary pilot work require highlighting. 
First, through the application of ARMA modelling of PRx, and LME modelling of PRx using TCD measures, 
in this unique cohort of patients with extended duration continuous TCD recordings, we have been able 
to produced LME models that accurately estimate observed PRx.  This is similar to our prior 
retrospective work in a large TB population with TCD.13  Further, the superior two models from this 
current cohort were of similar AMRA and mixed-effects structure to those discovered in the prior work, 
as confirmed through the principle of parsimony.  This provides some validation of the previous work, 
and also provides some evidence to support these models regardless of the duration of TCD recording 
analyzed. In addition, the bias on Bland-Altman analysis comparing observed to estimated PRx displayed 
the same underestimation bias seen in our previous work, with acceptable agreement. 
Second, as with our previous work,13 the general fixed effects versions of our top two models performed 
poorly in estimating PRx, with continuous significant autocorrelation in the model residuals. As 
mentioned within the methods section, these models were subsequently not reported further. This 
again confirms patient-by-patient heterogeneity, limiting the extrapolation of this work to other general 
TBI populations.  
Third, the current, and previous,13 ARMA works demonstrate the strong relationship between measures 
of CBV (ie. ICP or PRx) and CBF (ie. CBFV or Sx_a/Mx_a). This strong association between measures of 
CBV and CBF is important to emphasize.  PRx, believed to be a measure of cerebrovascular pressure 
reactivity, relies on the correlation between vasogenic slow-wave fluctuations in ICP and MAP.  ICP in 
this instance is considered a surrogate measure of pulsatile CBV.  Thus, PRx is measuring changes in CBV 
in response to changes in MAP, with the corresponding correlation representing cerebral pressure 
autoregulation and having been validated to measure the lower-limit of autoregulation in various 
experimental models.6,14,15 Whereas, the TCD based cerebrovascular reactivity indices (ie. Sx_a and 
Mx_a) are based on the correlation between slow-wave fluctuations in CBFV and MAP.  Thus, TCD based 
indices may be considered to be closer measures of flow than those based on non-CBF/CBFV measures. 
The main limiting factor for TCD measures is the labor-intensive nature inherent with classic TCD devices 
leading to short and interrupted recordings.  Thus, the application of TCD for regular continuous 
monitoring of cerebrovascular reactivity has been limited, with no experimental studies in existence 
validating them as measures actual of pressure autoregulation. Through demonstrating the strong link 
between PRx and Sx_a/Mx_a, we have demonstrated that TCD based flow measures are close in relation 
to the validated pressure autoregulation measure PRx However, it also must be acknowledged this 
relationship between volume and flow is not necessarily the same across all patients, as exemplified by 
the poor performance of general fixed effects models and the need of LME modelling demonstrating 
clearly that the flow/volume relationship varies from patient to patient. 
Fourth, we demonstrated for the first time in the literature the ability to estimate PRx using non-
invasive TCD surrogates.  Comparing pPRx to the observed PRx values in the top two models, the 
correlation is of moderate strength with a linear relationship between the two and acceptable 
agreement on Bland-Altman analysis. However, a similar underestimation bias for pPRx is present on 
Bland-Altman analysis. Further, the relationship between pPRx and the observed PRx was not 1:1, 
indicating the prediction is not perfect.  This is despite having very strong correlations between the 
estimated PRx and observed PRx during the model training phase.  This potentially suggests model over 
fitting during the training, though it must be acknowledged the current work is mainly a proof of 
concept and pilot analysis. Much further work is required to optimize the prediction models. 
Fifth, for the first time in the literature we successfully applied the emerging robotic TCD technology for 
extended duration recording in critically ill TBI patients.   
Finally, this work is based on only 10 patients and is entirely preliminary with results that are not 
generalizable at this time. Thus, this type of modelling and prediction of PRx should not be conducted 
outside of a research setting.  Much further work is required for validation.  
 
Limitations 
As with our previous work in this area, the patient population was heterogeneous in terms of age, intra-
cranial injury patterns and therapies directed at ICP/CPP goals.  These heterogeneities could impact 
signal fluctuations and the results obtained for the time series modelling conducted.  Though in 
comparison to our larger time series work in TBI, the results of the modelling within this preliminary 
pilot study were similar, as described above. 
Second, our patient numbers were small, at only 10.  For the purpose of this type of analysis we chose 
only to look at patients with 3 to 4 hours of completely uninterrupted ICP and TCD recordings and thus 
the dataset, whilst small, is of exceptional length for routine clinical recordings.  The requirement for 
interrupted continuous TCD is a significant limitation with the described modelling, as conventional TCD 
is currently heavily limited by artifact and signal loss. The application of the robotic TCD mitigated this in 
our study, however this technology is relatively new and not without its own limitations, including 
patient eligibility (ie. no decompressive craniectomy, no cervical spine immobilization devices, etc.), 
because of the robotic probe relatively bulky design. Furthermore, even with the application of robotic 
TCD, it remains difficult to obtain continuous extended duration recordings given patient motion, 
bedside procedures and transport for routine and emergent neuro-imaging.  As robotic and automated 
TCD technology improves, we expect to be able to obtain extended duration uninterrupted recordings 
throughout a patient’s ICU stay.  Thus, even though the current results are limited given patient 
numbers, they provide the platform for future applications once technology catches up with the 
demands of this type of modelling/prediction. 
Third, the ARIMA structure highlighted for PRx, and the LME models within this study may not be widely 
applied outside this population.  This was also mentioned in our previous publication on this topic.  
There exists the potential for patient specific ARIMA structures, and thus the models described in our 
studies should not be applied clinically. Furthermore, as mentioned above, the general fixed effects 
versions of our top two models performed poorly in the estimation of PRx, resulting in persistently 
significant residual lags.  This also suggests significant patient-by-patient heterogeneity, negating the 
extrapolation of these results to other general TBI populations at this time. Further work on PRx, 
amongst other physiologic measures in TBI, is required in larger patient populations in order to 
determine the exact high frequency time series behavior.    
Finally, the statistical methodology employed within this study is quite complex. Thus, the wide spread 
applicability of these techniques is currently limited.  However, with the increasing availability of real-
time bedside computing software such constraints are becoming less important as even mathematically 
sophisticated models can be handled automatically allowing for a much more user-friendly application 
of such techniques.  Such functions will automate much of the analysis described in our works on time 
series, requiring limited user input.  This will hopefully bring this type of work to the wider clinical world 
for future multi-center validation studies.  
 
Conclusions: 
Through the application of ARMA and LME modelling, it is possible to estimate PRx using non-invasive 
TCD measures, such as Sx_a and Mx_a.  This is the first preliminary attempts at doing so.  Much further 
work is required prior to application within a clinical setting, as this the current work should be 
considered experimental at this time. 
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Table 1:  LME Models with PRx (2,0,2) ARIMA Structure – Entire Population 
LME Model  PRx ARIMA Structure AIC BIC  LL 
Fixed Effects Random Effects p q 
PRx ~ Sx_a intercept 2 2 -1543.672 -1499.833 779.8362 
PRx ~ Mx_a intercept 2 2 -1502.348 -1458.509 759.1738 
PRx ~ Sx_a + Mx_a intercept 2 2 -1550.704 -1501.385 784.3520 
PRx ~ Sx_a Intercept + Sx_a 2 2 -1564.957 -1510.159 792.4768 
PRx ~ Mx_a Intercept + Mx_a 2 2 -1516.367 -1461.569 768.1836 
PRx ~ Sx_a + Mx_a Intercept + Sx_a + Mx_a 2 2 -1597.345 -1520.627 812.6726 
AIC = Akaike Information Criterion, ARIMA = auto-regressive integrative moving average, BIC = Bayesian Information Criterion,  FVm = mean TCD flow velocity, FVs = TCD based 
systolic flow velocity, ICP = intra-cranial pressure, LL = log likelihood, LME = linear mixed effects model, p = auto-regression parameter for ARIMA model, MAP = mean arterial 
pressure, PRx = pressure reactivity index (correlation between ICP and MAP), q = moving average parameter for ARIMA model, Sx_a = systolic flow index (correlation between 
TCD based FVs and MAP), TCD = transcranial Doppler. *Note: bolded value represents the most appropriate ARIMA structure and LME model for the patient population tested, 
based on principle of parsimony, lowest AIC and BIC.   There was no integrative parameter (ie. “d” parameter) included within the ARIMA models, given stationarity testing during 
patient examples (see appendix A and Methodology section of manuscript). 
 
Figure 1:  Example of Recording Set up for ICP, NIRS and Robotic TCD 
 
 
ICP = intra-cranial pressure, NIRS = near infrared spectroscopy, TCD = transcranial Doppler.  Panel A: Displays left front bolt for 
ICP monitor, bifrontal NIRS pads (black bi-lobed pads on forehead), and robotic TCD secured with headband (black arrows 
denote the robotic drives which control TCD probe). Panel B: displays same as Panel A but from the side. Panel C: Delica EMS 9D 
TCD program display, showing TCD cerebral blood flow velocity wave form, M-mode display and automatic correction system 
(black hashed arrow – indicating the automated search pattern for the TCD correction algorithm, insonating at multiple sites, 
finding the area with superior signal quality). 
 Figure 2: ACF and PACF for PRx – Patient Example 
 
ACF = autocorrelation function, a.u. = arbitrary units, PACF = autocorrelation function, PRx = pressure reactivity index 
(correlation between intracranial pressure and mean arterial pressure). Panel A: ACF plot displaying a rapid decay of significant 
PRx lag, suggesting stationarity. Panel B: PACF plot, also displaying rapid decay of significant PRx lags.  
 
Figure 3: Residual Plots for PRx (2,0,2) ARIMA Model and their ACF and PACF – A patient example 
 
ACF = autocorrelation function, PACF = autocorrelation function, PRx = pressure reactivity index (correlation between 
intracranial pressure and mean arterial pressure). Panel A: displays the residual plot for the ARIMA model in this patient 
example. Panel B: ACF plot displaying no significant lags with (2,0,2) ARIMA model for PRx. Panel C: PACF plot, also no 
significant lags with (2,0,2) ARIMA model for PRx.  
  
Figure 4: Linear Regression Between Observed and Estimated PRx – Using Estimated PRx From Two Best LME Models 
 
a.u. = arbitrary units, ICP = intracranial pressure, LME = linear mixed effects, MAP = mean arterial pressure, PRx = pressure 
reactivity index (correlation between ICP and MAP). Panel A: LME model – PRx ~ Sx_a (random effects with intercept and Sx_a), 
Panel B: LME model – PRx ~ Sx_a + Mx_a (random effects with intercept, Sx_a and Mx_a).  Coef = coefficients, form linear model 
between observed PRx and model estimated PRx.  Dotted straight line – represents the relationship “y = x”, for comparison to 
our two models. 
 
 
Figure 5: Linear Regression Between Observed and Predicted PRx – Using Predicted PRx From Two Best LME Models 
 
a.u. = arbitrary units, ICP = intracranial pressure, LME = linear mixed effects, MAP = mean arterial pressure, PRx = pressure 
reactivity index (correlation between ICP and MAP). Panel A: LME model – PRx ~ Sx_a (random effects with intercept and Sx_a), 
Panel B: LME model – PRx ~ Sx_a + Mx_a (random effects with intercept, Sx_a and Mx_a).  Coef = coefficients, form linear model 
between observed PRx and model estimated PRx.   
 
 
 
 
Appendix A – QQ, Residual Density, ACF and PACF Plots for Top Two LME Models 
 
1. PRx ~ Sx_a LME Model (with random effects by patient in intercept and coefficients) 
 
QQ Plot 
 
 
Residual Density Plot 
 
 
 
ACF Plot 
 
 
PACF Plot 
 
 
2. PRx ~ Sx_a + Mx_a LME Model (with random effects by patient in intercept and coefficients) 
QQ Plot 
 
 
Residual Density Plot 
 
 
 
 
 
 
ACF Plot 
 
 
PACF Plot 
 
 
 
 
Appendix B – Bland Altman Analysis for Estimated vs. Observed PRx for Top Two LME Models 
*Grand mean Fisher transformed data utilized for Bland-Altman analysis 
 
1. PRx ~ Sx_a (with random effects introduced into intercept and coefficient) 
$lower.limit 
[1] -0.0628747 
 
$mean.diffs 
[1] -0.003253664 
 
$upper.limit 
[1] 0.05636738 
 
$lines 
 lower.limit   mean.diffs  upper.limit  
-0.062874705 -0.003253664  0.056367377  
 
$CI.lines 
lower.limit.ci.lower lower.limit.ci.upper   mean.diff.ci.lower   mean.diff.ci
.upper upper.limit.ci.lower  
         -0.10056477          -0.02518464          -0.02501403           0.01
850671           0.01867731  
upper.limit.ci.upper  
          0.09405744  
 
$critical.diff 
[1] 0.05962104 
 
 
 
2. PRx ~ Sx_a + Mx_a (with random effects introduced into intercept and coefficient) 
$lower.limit 
[1] -0.0664208 
 
$mean.diffs 
[1] -0.003062638 
 
$upper.limit 
[1] 0.06029553 
 
$lines 
 lower.limit   mean.diffs  upper.limit  
-0.066420801 -0.003062638  0.060295526  
 
$CI.lines 
lower.limit.ci.lower lower.limit.ci.upper   mean.diff.ci.lower   mean.diff.ci
.upper upper.limit.ci.lower  
         -0.10647333          -0.02636828          -0.02618697           0.02
006170           0.02024300  
upper.limit.ci.upper  
          0.10034805  
 
$critical.diff 
[1] 0.06335816 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix C – Bland Altman Analysis for Predicted vs. Observed PRx for Top Two LME Models 
*Grand mean Fisher transformed data utilized for Bland-Altman analysis 
 
1. PRx ~ Sx_a (with random effects introduced into intercept and coefficient) 
$lower.limit 
[1] -0.2826737 
 
$mean.diffs 
[1] -0.05195699 
 
$upper.limit 
[1] 0.1787597 
 
$lines 
lower.limit  mean.diffs upper.limit  
-0.28267367 -0.05195699  0.17875969  
 
$CI.lines 
lower.limit.ci.lower lower.limit.ci.upper   mean.diff.ci.lower   mean.diff.ci
.upper upper.limit.ci.lower  
         -0.42852364          -0.13682371          -0.13616351           0.03
224952           0.03290972  
upper.limit.ci.upper  
          0.32460965  
 
 
$critical.diff 
[1] 0.2307167 
 
 
 
2. PRx ~ Sx_a + Mx_a (with random effects introduced into intercept and coefficient) 
$lower.limit 
[1] -0.2932762 
 
$mean.diffs 
[1] -0.04899657 
 
$upper.limit 
[1] 0.195283 
 
$lines 
lower.limit  mean.diffs upper.limit  
-0.29327618 -0.04899657  0.19528303  
 
$CI.lines 
lower.limit.ci.lower lower.limit.ci.upper   mean.diff.ci.lower   mean.diff.ci
.upper upper.limit.ci.lower  
         -0.44770008          -0.13885227          -0.13815326           0.04
016011           0.04085912  
upper.limit.ci.upper  
          0.34970694  
 
 
$critical.diff 
[1] 0.2442796 
 
 
  
 
